A Study of XZB-0004 in Patients With Solid Tumors

Advanced Solid Tumor Clinical Trial

Official title:

A Phase I, Open-label, Dose-escalation Study of the Safety, Pharmacokinetics and Efficacy of the XZB-0004 in Patients With Solid Tumours

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05772455
• Other study ID #: XZB-0004-1001
• Status: Not yet recruiting
• Phase: Phase 1
• Start date: April 2023
• Est. completion date: February 2027

Study information

• Verified date: March 2023
• Source: Xuanzhu Biopharmaceutical Co., Ltd.
• Contact: Xiujie Zhang
• Phone: +86-13671737230
• Email: zhangxiujie[@]xuanzhubio.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

XZB-0004 is a novel and potent small molecule inhibitor of receptor tyrosine kinase AXL.

This is an open-label, multicentre phase I study of XZB-0004 in patients with solid tumors. Part 1 is a dose-escalation study to evaluate the safety, pharmacokinetic (PK), and pharmacodynamic profile of XZB-0004, and then to identify a safe and pharmacologically active dose for evaluation in subsequent cohorts or clinical studies. Part 2 is a study to evaluate the efficacy and safety of XZB-0004 combined with Peamplimab in patients with NSCLC or advanced solid tumors.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 128
• Est. completion date: February 2027
• Est. primary completion date: June 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Patient has signed informed consent before any trial related activities.

2. Be 18 years of age or older and less than 75 years at the time of signing the informed consent.

3. Part 1: Have a histologically or cytologically confirmed diagnosis of a solid tumour malignancy; Part 2:Have a histologically or cytologically confirmed diagnosis of a NSCLC or solid tumour malignancy.

4. Have evaluable (for Part 1) or measurable (for Part 2) disease as the Response Evaluation Criteria in Solid Tumours (RECIST) 1.1.

5. Have a performance status score of 0 or 1 according to the Eastern Cooperative Oncology Group (ECOG) scale.

6. Have adequate organ function.

7. Have recovered to = grade 1 or Meet the requirements of the study from the effects of any prior cancer therapy, except for alopecia; irreversible neuropathy should have recovered to = grade 2.

8. Have a life expectancy greater than 3 months.

9. Eligible patients (male and female) who are fertile must agree to at least use a reliable contraceptive method with partner.

10. Willingness to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures.

Exclusion Criteria:

1. Previous use of AXL inhibitors and immunotherapy was consistent with protocol requirements.

2. Received anti-tumor therapy such as chemotherapy, radiotherapy, biotherapy, endocrine therapy, immunotherapy or other therapy within 4 weeks prior to the first dose of the investigational drug.

3. Received other unmarketed investigational drugs or treatments within 4 weeks or 5 times the elimination half-life prior to the first dose of the investigational drug.

4. Treatment with systemic glucocorticoids (prednisone > 10mg per day or equivalent) or other immunosuppressive agents within 14 days before the first dose of a trial drug.

5. Inability to swallow, intestinal obstruction or other factors that affect the taking and absorption of the drug.

6. Patient with heart function impaired or clinically significant heart disease.

7. Any condition or illness that, in the opinion of the Investigator, would interfere with the evaluation of the safety of the study drug.

8. History of immune deficiencies, including positive HIV antibody tests.

9. Patient is in the active stage of HBV or HCV.

10. History of solid organ transplant or bone marrow transplant.

11. Any other malignant tumor has been diagnosed within 5 years.

12. Has known Primary tumor of the central nervous system or central nervous system metastase.

13. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage were present within 4 weeks before the first dose of the trial drug.

14. Subjects with psychiatric disorders that may affect trial compliance.

15. history of Alcoholism or drug abuse.

16. Pregnant or breastfeeding.

17. The researchers considered that there were some cases that were not suitable for inclusion.

Related Conditions & MeSH terms

• Advanced Solid Tumor
• Neoplasms
• NSCLC

Intervention

Drug:
• XZB-0004
Part 1a: 100mg BID, 150mg BID, and 200mg BID of XZB-0004 are planned to be evaluated, and the possibility of exploring higher or lower doses is not ruled out. Continuous administration of XZB-0004 for 21 days is a treatment cycle. Part 1b: XZB-0004 in combination with peramprizumab in subjects with advanced NSCLC or solid tumors, starting at a dose level down from the RP2D of XZB-0004 monotherapy- cohort 1: Advanced or metastatic NSCLC with advanced disease progression after treatment with PD-1 or PD-L1 inhibitors; cohort 2: Advanced or metastatic NSCLC with advanced disease progression after platinum-containing chemotherapy without prior use of any immunocheckpoint inhibitors; cohort3: Advanced or metastatic solid tumors that cannot be radically cured by surgery or local therapy, including but not limited to urothelial carcinoma, melanoma, etc. Subjects had disease progression since last antitumor therapy, no availability or intolerance or refusal of standard therapy.

Locations

Country	Name	City	State
China	Shanghai Pulmonary Hospital	Shanghai	Shanghai

Sponsors (1)

Lead Sponsor	Collaborator
Xuanzhu Biopharmaceutical Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Maximum tolerated dose (MTD) (for Part 1a)	Determine MTD of XZB-0004	Up to 3 weeks
Primary	Recommended phase 2 dose (RP2D)(for Part 1a)	Determine RP2D of XZB-0004	Up to 3 weeks
Primary	Overall Response Rate (ORR) (for Part 1b)	Number of participants who achieved a best response of either complete response (CR) or partial response (PR) during treatment evaluated by investigators according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1	Up to 2-3 years
Secondary	Pharmakinetic parameter - AUC0-t (for Part 1a and Part 1b)	To determine AUC0-t of XZB-0004	Up to 63 days
Secondary	Pharmakinetic parameter - AUC0-8 (for Part 1a and Part 1b)	To determine AUC0-8 of XZB-0004	Up to 63 days
Secondary	Pharmakinetic parameter - Cmax (for Part 1a and Part 1b)	To determine Cmax of XZB-0004	Up to 63 days
Secondary	Pharmakinetic parameter - Tmax (for Part 1a and Part 1b)	To determine Tmax of XZB-0004	Up to 63 days
Secondary	Pharmakinetic parameter - t½ (for Part 1a and Part 1b)	To determine t½ of XZB-0004	Up to 63 days
Secondary	Pharmakinetic parameter - CL/F (for Part 1a and Part 1b)	To determine CL/F of XZB-0004	Up to 63 days
Secondary	Pharmakinetic parameter - Vz/F (for Part 1a and Part 1b)	To determine Vz/F of XZB-0004	Up to 63 days
Secondary	Overall Response Rate (ORR) (for Part 1a)	Number of participants who achieved a best response of either complete response (CR) or partial response (PR) during treatment evaluated by investigators according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1	Up to 2-3 years
Secondary	Progression free survival (PFS) (for Part 1a and Part 1b)	PFS is defined as the time from the date of first dose of XZB-0004 till the first documentation of disease progression (per RECIST v1.1 criteria) assessed by the investigator or death due to any cause (whichever occurs first).	Up to 2-3 years
Secondary	Duration of response (DOR) (for Part 1a and Part 1b)	DoR is defined as the duration from the first documentation of objective response to the first documented disease progression or death due to any cause, whichever occurs first.	Up to 2-3 years
Secondary	Disease control rate (DCR) (for Part 1a and Part 1b)	DCR is defined as the proportion of subjects with CR, PR, or SD, based on RECIST v1.1.	Up to 2-3 years
Secondary	Overall survival (OS) (for Part 1a and Part 1b)	OS is the time from the date of first dose of XZB-0004 to death due to any cause.	Up to 2-3 years
Secondary	Incidence and severity of adverse events (AEs)(for Part 1b)	An adverse event (AE) is any untoward medical occurrence or the deterioration of existing medical event in a clinical study subject administered an investigational drug, which does not necessarily have an unequivocal causal relationship with the investigational product.	Up to 2-3 years